Skip to main content
KARD
NASDAQ Life Sciences

Kardigan Raises $400M in Upsized IPO, Pricing Shares at $16

Tom Rudovsky · Reported by Reuters
More coverage: Healthcare
Sentiment info
Positive
Importance info
9
Price
--
Mkt Cap
--
52W Low
--
52W High
--
52W Position
Off High
Rel. Volume
Market data snapshot near publication time

Summary

Heart drug developer Kardigan successfully raised $400 million in an upsized initial public offering, selling 25 million shares at $16 each, the top of its target range. This significant capital infusion will fund the clinical development of its three late-stage experimental therapies, including treatments for genetic dilated cardiomyopathy and calcific aortic valve stenosis. The strong investor demand, evidenced by the upsized offering and top-range pricing, provides crucial funding for this clinical-stage biotech ahead of its Nasdaq debut on Thursday.

This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Reuters.


Price Chart

Share this article

Copied!

KARD - Latest Insights

KARD
Nov 12, 2026, 7:02 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $15.68
Real-time Price: $13.82 info
Change: -$1.86 (-12%) info
Market Cap: $1.292B info
KARD
Nov 06, 2026, 4:06 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $15.93
Real-time Price: $13.82 info
Change: -$2.11 (-13%) info
Market Cap: $1.292B info
KARD
Nov 06, 2026, 4:05 PM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: $15.52
Real-time Price: $13.82 info
Change: -$1.70 (-11%) info
Market Cap: $1.292B info
KARD
Aug 11, 2026, 7:10 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $20.41
Real-time Price: $13.82 info
Change: -$6.59 (-32%) info
Market Cap: $1.292B info
KARD
Aug 11, 2026, 7:00 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $20.41
Real-time Price: $13.82 info
Change: -$6.59 (-32%) info
Market Cap: $1.292B info